ClinVar Miner

Submissions for variant NM_000316.3(PTH1R):c.299G>A (p.Gly100Asp) (rs41290646)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Illumina Clinical Services Laboratory,Illumina RCV000327085 SCV000444767 likely benign Chondrodysplasia Blomstrand type 2017-04-27 criteria provided, single submitter clinical testing This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to determine this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign.
Illumina Clinical Services Laboratory,Illumina RCV000362244 SCV000444768 likely benign Metaphyseal chondrodysplasia, Jansen type 2017-04-27 criteria provided, single submitter clinical testing This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to determine this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign.
Center for Pediatric Genomic Medicine,Children's Mercy Hospital and Clinics RCV000514382 SCV000610506 likely benign not provided 2017-08-10 criteria provided, single submitter clinical testing
Invitae RCV000514382 SCV001117380 benign not provided 2020-11-26 criteria provided, single submitter clinical testing
ARUP Laboratories, Molecular Genetics and Genomics,ARUP Laboratories RCV001285625 SCV001472089 likely benign none provided 2020-01-09 criteria provided, single submitter clinical testing
Department of Pathology and Laboratory Medicine,Sinai Health System RCV001357210 SCV001552602 benign not specified no assertion criteria provided clinical testing The PTH1R p.Gly100Asp variant was identified in 1 of 168 proband chromosomes (frequency: 0.00595) from individuals with Ollier disease and was present in 1 of 444 control chromosomes (frequency: 0.00225) from healthy individuals (Couvineau_2008_PMID:18559376). The variant was identified in dbSNP (ID: rs41290646), LOVD 3.0 and ClinVar (classified as likely benign by Illumina and Center for Pediatric Genomic Medicine, and as benign by Invitae). The variant was identified in control databases in 563 of 282480 chromosomes (2 homozygous) at a frequency of 0.001993 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Database March 6, 2019, v2.1.1). The variant was observed in the following populations: European (non-Finnish) in 471 of 128948 chromosomes (freq: 0.003653), Other in 15 of 7214 chromosomes (freq: 0.002079), European (Finnish) in 29 of 25098 chromosomes (freq: 0.001155), Latino in 38 of 35402 chromosomes (freq: 0.001073), Ashkenazi Jewish in 3 of 10362 chromosomes (freq: 0.00029), African in 5 of 24916 chromosomes (freq: 0.000201) and South Asian in 2 of 30598 chromosomes (freq: 0.000065), but was not observed in the East Asian population. The p.Gly100 residue is conserved in mammals and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) provide inconsistent predictions regarding the impact to the protein; this information is not very predictive of pathogenicity. The variant occurs outside of the splicing consensus sequence and 1 of 4 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) predict a greater than 10% difference in splicing; this is not very predictive of pathogenicity. Functional in vitro assays demonstrated that the p.Gly100Asp variant results in <5% ligand binding compared to wildtype, however localization and receptor function was not affected by the variant, suggesting no functional effect (Couvineau_2008_PMID:18559376). In summary, based on the above information this variant meets our laboratory's criteria to be classified as benign.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.